Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
Rhea-AI Summary
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases, has announced its participation in two major investor conferences this November. Natalie Holles, CEO, will present at the Stifel 2024 Healthcare Conference on November 19 at 3:00 p.m. EST, while Chris Murphy, CFO, will speak at the Jefferies London Healthcare Conference on the same day at 11:00 a.m. GMT. Live audio webcasts will be available on Third Harmonic's website, with replays accessible for 90 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, THRD gained 7.68%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences:
- Natalie Holles, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 3:00 p.m. EST
- Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:00 a.m. GMT / 6:00 a.m. EST
A live audio webcast of each fireside chat will be available within the Investors & Media section of the Third Harmonic Bio website. Archived replays will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
When is Third Harmonic Bio (THRD) presenting at the Stifel Healthcare Conference 2024?
What time is Third Harmonic Bio's (THRD) presentation at the Jefferies London Healthcare Conference?
How long will Third Harmonic Bio's (THRD) November 2024 conference webcasts be available?
